STTK
Shattuck Labs, Inc.NASDAQHealthcare$6.42+2.72%ClosedMarket Cap: $307.5M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
8.09
P/S
307.54
EV/EBITDA
-5.48
DCF Value
$0.63
FCF Yield
-13.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-177.1%
Operating Margin
-5142.7%
Net Margin
-4880.9%
ROE
-65.0%
ROA
-53.6%
ROIC
-61.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-12.6M | $-0.12 |
| FY 2025 | $1.0M | $-48.8M | $-0.70 |
| Q3 2025 | $1.0M | $-10.1M | $-0.14 |
| Q2 2025 | $0.00 | $-12.5M | $-0.24 |
Analyst Ratings
View AllCitigroupNeutral
2026-03-13WedbushOutperform
2026-03-06CitigroupNeutral
2026-01-06HC Wainwright & Co.Buy
2025-12-01NeedhamHold
2025-08-14Trading Activity
Insider Trades
View AllPandite Arundathy N.officer: Chief Medical Officer
SellTue Jan 27
Stout Stephenofficer: See Remarks
SellTue Jan 27
DeYoung Casiofficer: Chief Business Officer
SellTue Jan 27
Neill Andrew Rofficer: Chief Financial Officer
SellTue Jan 27
Stout Stephenofficer: See Remarks
SellTue Jan 13
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.29
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.